세계의 폐기종 치료 시장 : 치료 유형별, 유형별, 최종 사용자별-기회 분석 및 산업 예측(2023-2032년)

Emphysema Treatment Market By Treatment Type (Medication, Oxygen Therapy, Surgery), By Type (Centriacinar, Panacinar, Others), By End User (Hospitals, Homecare, Specialty Centres, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,820 ￦ 8,121,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,870 ￦ 13,772,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

세계의 폐기종 치료 시장은 2022년에 63억 달러로 평가되었고, 2023년부터 2032년까지 CAGR 3.3%로 성장할 전망이며, 2032년에는 87억 달러에 달할 것으로 예측되고 있습니다.

폐기종은 폐의 기낭(폐포) 손상을 특징으로 하는 만성 질환으로 호흡 곤란을 초래합니다. 이 손상은 자극물, 특히 담배 연기에 장기간 노출되어 발생합니다. 기낭의 섬세한 벽이 손상되면 탄력이 없어져 폐에서 잘 숨을 내쉴 수 없습니다. 그 결과 폐에 공기가 담겨 폐가 부풀어 오르고 호흡 곤란, 기침, 천명 및 기타 호흡기 증상을 유발합니다. 폐기종의 치료는 주로 증상의 관리와 폐의 추가 손상의 예방에 중점을 둡니다. 기도 주위의 근육을 이완시키고 기류를 개선하는 기관지 확대제와 같은 약물이 일반적으로 처방됩니다. 심한 경우에는 폐의 염증을 억제하기 위해 코르티코스테로이드가 사용됩니다. 혈중 산소 농도가 낮은 경우에는 산소 요법이 필요할 수도 있습니다. 진행되면 폐기종으로 인한 호흡 문제가 심각한 환자에게 폐 용량 감소 수술과 폐 이식과 같은 수술 옵션이 고려됩니다.

세계의 폐기종 치료 시장의 성장은 폐기종 이환율 증가와 세계 흡연자 수의 급증으로 인한 것으로 예상됩니다. 폐기종은 노인 인구의 급증, 환경 오염의 우려적인 증가, 세계 흡연 유병률 증가로 인해 세계적으로 점점 유행하고 있습니다. 예를 들어, 미국 국립 의료 도서관이 발표한 2022년 논문에 따르면, 미국에서 폐기종의 유병률은 약 1,400만 명이며, 미국을 대표하는 COPD 질환입니다.

또한 대기 오염, 산업 배출물, 유해 미립자 물질 노출 등 환경 요인은 특히 오염 수준이 높은 경향이 있는 도시 지역에서 폐기종 발병 위험을 상승시킵니다. 세계의 폐기종 발생률이 증가하면 이 만성 질환을 관리하기 위한 효과적인 치료 개입이 급증하고, 이로 인해 세계 폐기종 치료 시장의 성장이 증가할 것으로 예상됩니다.

또한 세계 흡연자 수 증가가 폐기종 치료 시장의 주요 추진력으로 부상하고 있습니다. 예를 들어, 세계보건기구(WHO)의 2021년판에 따르면 세계 인구의 22.3%가 담배를 사용하고 있으며, 130만명의 담배 흡연자가 중저소득국에 거주하고 있습니다. 세계 흡연 습관을 가진 사람이 증가함에 따라 폐기종 발생률도 동시에 상승하고 있습니다. 흡연은 폐 기능의 악화를 진행시키고 기존의 호흡기 질환을 악화시키기 때문에 폐기종 발병의 주요 위험 인자로 널리 인식되고 있습니다. 그 결과, 흡연자 수 증가는 폐기종과 관련된 증상을 관리하고 환자의 QOL을 개선하기 위한 효과적인 치료에 대한 수요 증가로 이어집니다. 따라서 세계의 흡연자 수 증가가 시장 성장을 가속할 것으로 예상됩니다.

세계의 폐기종 치료 시장은 치료 유형, 유형, 최종 사용자, 지역으로 구분됩니다. 치료 유형별로 시장은 약물 요법, 산소 요법, 수술로 나뉩니다. 유형별로는 센트리아 시나르, 파나시나르 등으로 구분됩니다. 최종 사용자별로는 병원, 재택치료, 전문센터 등으로 분류됩니다. 지역별로는 북미(미국, 캐나다, 멕시코), 유럽(프랑스, 독일, 이탈리아, 스페인, 영국, 기타 유럽), 아시아태평양(중국, 일본, 인도, 한국, 호주 및 기타 아시아태평양), LAMEA(브라질, 남아프리카, 사우디아라비아, 기타 LAMEA)에서 분석됩니다.

이해관계자를 위한 주요 이점

• 본 보고서에서는 2022년부터 2032년까지의 폐기종 치료 시장 분석 시장 부문, 현재의 동향, 추정 및 역학의 정량적 분석을 제공하여 폐기종 치료 시장의 유력한 기회를 확인합니다.
• 시장 성장 촉진요인, 시장 성장 억제요인, 시장 기회와 관련된 정보와 함께 시장 조사를 기재하고 있습니다.
• Porter's Five Forces 분석은 이해관계자들이 이익에 중점을 둔 비즈니스 결정을 내리고 공급업체와 구매자의 네트워크를 강화할 수 있도록 구매자 및 공급업체의 잠재력을 보여줍니다.
• 폐기종 치료 시장 세분화의 상세한 분석을 통해 시장 기회를 파악할 수 있습니다.
• 각 지역의 주요 국가는 세계 시장에 대한 수익 공헌도에 따라 매핑됩니다.
• 시장 진출기업의 포지셔닝은 벤치마킹을 용이하게 하고, 시장 진출기업의 현재 포지션의 명확한 이해를 기재하고 있습니다.
• 지역별 및 세계의 폐기종 치료 시장 동향, 주요 기업, 시장 부문, 용도 부문, 시장 성장 전략 등의 분석을 포함합니다.

이 보고서에서 가능한 맞춤설정(추가 비용 및 일정이 있습니다.)

• 국가, 지역, 세계 수준의 환자 및 역학 데이터
• 규제 가이드라인
• 고객의 관심에 따른 추가 기업 프로파일
• 국가별 또는 지역별 추가 분석-시장 규모 및 예측
• 기업 프로파일 확대 목록
• 과거 시장 데이터
• SWOT 분석

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장 정의 및 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진요인
    • 폐기종 환자 증가
    • 세계의 흡연자 수 급증
    • 폐기종의 원인이 되는 대기 오염 증가
  • 억제요인
    • 고액의 치료비
    • 약제에 따른 부작용
  • 기회
    • 신흥 시장에서의 성장 기회

제4장 폐기종 치료 시장 : 치료 유형별

• 개요
• 약제 요법
  • 약제 요법에 의한 폐기종 치료 시장 : 유형별
• 산소 요법
• 수술 요법

제5장 폐기종 치료 시장 : 유형별

• 개요
• 센트리아 시나르
• 파나시나르
• 기타

제6장 폐기종 치료 시장 : 최종 사용자별

• 개요
• 병원
• 재택치료
• 전문센터
• 기타

제7장 폐기종 치료 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타
• 라틴아메리카, 중동 및 아프리카
  • 브라질
  • 사우디아라비아
  • 남아프리카
  • 기타

제8장 경쟁 구도

• 서문
• 주요 성공 전략
• 주요 10개사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2022년)

제9장 기업 프로파일

• AstraZeneca
• Boehringer Ingelheim International GmbH
• GlaxoSmithKline Plc.
• Viatris Inc.
• Novartis AG
• Orion Corporation
• Teva Pharmaceutical Industries Ltd.
• Verona Pharma Plc.
• Koninklijke Philips NV
• Inogen, Inc.

AJY

영문 목차

영문목차

The global emphysema treatment market was valued at $6.3 billion in 2022, and is projected to reach $8.7 billion by 2032, growing at a CAGR of 3.3% from 2023 to 2032.

Emphysema is a chronic condition characterized by damage to the air sacs (alveoli) in the lungs, leading to difficulty in breathing. This damage is caused by long-term exposure to irritants, most commonly cigarette smoke. When the delicate walls of the air sacs are damaged, they lose their elasticity, making it difficult for the lungs to exhale properly. As a result, air is trapped in the lungs, causing them to inflate and leading to shortness of breath, coughing, wheezing, and other respiratory symptoms. Treatment for emphysema focuses primarily on managing symptoms and preventing further lung damage. Medications such as bronchodilators, which help to relax the muscles around the airways and improve airflow, are commonly prescribed. In more severe cases, corticosteroids are used to reduce inflammation in the lungs. Oxygen therapy may be necessary for those with low blood oxygen levels. In advanced stages, surgical options like lung volume reduction surgery or lung transplantation is considered for patients with severe breathing issues due to emphysema .

The growth of the global emphysema treatment market is expected to be driven by rise in incidence of emphysema and surge in number of smokers globally. Emphysema has been increasingly prevalent across the globe due to surge in geriatric population, alarming rise in environmental pollution, and increase in prevalence of smoking worldwide. For instance, according to 2022 article published by the National Library of Medicine, the prevalence of emphysema in the U.S. is approximately 14 million and is leading COPD disorder across the U.S.

In addition, environmental factors such as air pollution, industrial emissions, and exposure to harmful particulate matter have escalated the risk of developing emphysema, especially in urban areas where pollution levels tend to be higher. The rise in incidence of emphysema globally has resulted in surge in effective therapeutic interventions to manage this chronic disease, which is expected to boost the growth of the global emphysema treatment market.

Furthermore, increase in the number of smokers globally has emerged as a key driving force of the emphysema treatment market. For instance, according to the World Health Organization (WHO) 2021, 22.3% world's population use tobacco with 1.3 million tobacco smokers residing in low- and middle-income countries. With increasing number of individuals adopting smoking habits worldwide, the incidence of emphysema has escalated simultaneously. Smoking is widely recognized as the primary risk factor for developing emphysema, as it leads to the progressive deterioration of lung function and exacerbates existing respiratory conditions. Consequently, the escalating number of smokers has contributed to a heightened demand for effective treatments to manage emphysema-related symptoms and improve patients' quality of life. Thus, rise in number of smokers globally is expected to drive the growth of the market.

The global emphysema treatment market is segmented into treatment type, type, end user, and region. By treatment type, the market is divided into medication, oxygen therapy, and surgery. Depending on type, it is segregated into centriacinar, panacinar, and others. On the basis of end user, it is classified into hospitals, home care, specialty centers, and others. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (France, Germany, Italy, Spain, UK, and rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The major players profiled in the report are AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Novartis AG, Orion Corporation, Viatris Inc., Inogen, Teva Pharmaceuticals, Koninklijke Philips N.V., and Verona Pharma.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the emphysema treatment market analysis from 2022 to 2032 to identify the prevailing emphysema treatment market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the emphysema treatment market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global emphysema treatment market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Patient/epidemiology data at country, region, global level
• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• SWOT Analysis

Key Market Segments

By End User

• Hospitals
• Homecare
• Specialty Centres
• Others

By Treatment Type

• Medication
  • Type
  • Bronchodilators
  • Steroids
  • Others
• Oxygen Therapy
• Surgery

By Type

• Centriacinar
• Panacinar
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Viatris Inc.
• Koninklijke Philips N.V.
• GlaxoSmithKline Plc.
• AstraZeneca
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim International GmbH
• Inogen, Inc.
• Orion Corporation
• Verona Pharma Plc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Moderate bargaining power of suppliers
  • 3.3.2. Low threat of new entrants
  • 3.3.3. Moderate threat of substitutes
  • 3.3.4. Moderate intensity of rivalry
  • 3.3.5. Moderate bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Increase in prevalence of emphysema cases.
    • 3.4.1.2. Surge in number of smokers globally.
    • 3.4.1.3. Increase in air pollution contributing to emphysema.
  • 3.4.2. Restraints
    • 3.4.2.1. High cost of treatment.
    • 3.4.2.2. Side effects associated with medications.
  • 3.4.3. Opportunities
    • 3.4.3.1. Growth opportunities in emerging markets.

CHAPTER 4: EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Medication
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
  • 4.2.4. Medication Emphysema Treatment Market by Type
• 4.3. Oxygen Therapy
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Surgery
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country

CHAPTER 5: EMPHYSEMA TREATMENT MARKET, BY TYPE

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Centriacinar
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Panacinar
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Others
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country

CHAPTER 6: EMPHYSEMA TREATMENT MARKET, BY END USER

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospitals
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Homecare
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Specialty Centres
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country
• 6.5. Others
  • 6.5.1. Key market trends, growth factors and opportunities
  • 6.5.2. Market size and forecast, by region
  • 6.5.3. Market share analysis by country

CHAPTER 7: EMPHYSEMA TREATMENT MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Treatment Type
  • 7.2.3. Market size and forecast, by Type
  • 7.2.4. Market size and forecast, by End User
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Treatment Type
    • 7.2.5.1.2. Market size and forecast, by Type
    • 7.2.5.1.3. Market size and forecast, by End User
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Treatment Type
    • 7.2.5.2.2. Market size and forecast, by Type
    • 7.2.5.2.3. Market size and forecast, by End User
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Treatment Type
    • 7.2.5.3.2. Market size and forecast, by Type
    • 7.2.5.3.3. Market size and forecast, by End User
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Treatment Type
  • 7.3.3. Market size and forecast, by Type
  • 7.3.4. Market size and forecast, by End User
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Treatment Type
    • 7.3.5.1.2. Market size and forecast, by Type
    • 7.3.5.1.3. Market size and forecast, by End User
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Treatment Type
    • 7.3.5.2.2. Market size and forecast, by Type
    • 7.3.5.2.3. Market size and forecast, by End User
    • 7.3.5.3. UK
    • 7.3.5.3.1. Market size and forecast, by Treatment Type
    • 7.3.5.3.2. Market size and forecast, by Type
    • 7.3.5.3.3. Market size and forecast, by End User
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Treatment Type
    • 7.3.5.4.2. Market size and forecast, by Type
    • 7.3.5.4.3. Market size and forecast, by End User
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Treatment Type
    • 7.3.5.5.2. Market size and forecast, by Type
    • 7.3.5.5.3. Market size and forecast, by End User
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Treatment Type
    • 7.3.5.6.2. Market size and forecast, by Type
    • 7.3.5.6.3. Market size and forecast, by End User
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Treatment Type
  • 7.4.3. Market size and forecast, by Type
  • 7.4.4. Market size and forecast, by End User
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Treatment Type
    • 7.4.5.1.2. Market size and forecast, by Type
    • 7.4.5.1.3. Market size and forecast, by End User
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Treatment Type
    • 7.4.5.2.2. Market size and forecast, by Type
    • 7.4.5.2.3. Market size and forecast, by End User
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Treatment Type
    • 7.4.5.3.2. Market size and forecast, by Type
    • 7.4.5.3.3. Market size and forecast, by End User
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Market size and forecast, by Treatment Type
    • 7.4.5.4.2. Market size and forecast, by Type
    • 7.4.5.4.3. Market size and forecast, by End User
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Treatment Type
    • 7.4.5.5.2. Market size and forecast, by Type
    • 7.4.5.5.3. Market size and forecast, by End User
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Treatment Type
    • 7.4.5.6.2. Market size and forecast, by Type
    • 7.4.5.6.3. Market size and forecast, by End User
• 7.5. LAMEA
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Treatment Type
  • 7.5.3. Market size and forecast, by Type
  • 7.5.4. Market size and forecast, by End User
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Treatment Type
    • 7.5.5.1.2. Market size and forecast, by Type
    • 7.5.5.1.3. Market size and forecast, by End User
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Market size and forecast, by Treatment Type
    • 7.5.5.2.2. Market size and forecast, by Type
    • 7.5.5.2.3. Market size and forecast, by End User
    • 7.5.5.3. South Africa
    • 7.5.5.3.1. Market size and forecast, by Treatment Type
    • 7.5.5.3.2. Market size and forecast, by Type
    • 7.5.5.3.3. Market size and forecast, by End User
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Market size and forecast, by Treatment Type
    • 7.5.5.4.2. Market size and forecast, by Type
    • 7.5.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. AstraZeneca
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. Boehringer Ingelheim International GmbH
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
• 9.3. GlaxoSmithKline Plc.
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. Viatris Inc.
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
  • 9.4.7. Key strategic moves and developments
• 9.5. Novartis AG
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
• 9.6. Orion Corporation
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
• 9.7. Teva Pharmaceutical Industries Ltd.
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
  • 9.7.7. Key strategic moves and developments
• 9.8. Verona Pharma Plc.
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
  • 9.8.7. Key strategic moves and developments
• 9.9. Koninklijke Philips N.V.
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
• 9.10. Inogen, Inc.
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance
  • 9.10.7. Key strategic moves and developments

관련자료